2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-103704
    LY2562175 1103500-20-4 99.49%
    LY2562175 is a potent and selective FXR agonist, with an EC50 of 193 nM.
    LY2562175
  • HY-10480A
    (R)-Fasiglifam 1234474-57-7 98.95%
    (R)-Fasiglifam is the isomer of Fasiglifam (HY-10480), and can be used as an experimental control. Fasiglifam (TAK-875) is a potent, selective and orally bioavailable GPR40 agonist with EC50 of 72 nM.
    (R)-Fasiglifam
  • HY-105946
    Hidrosmin 115960-14-0
    Hidrosmin, a flavonoid, is derived from Diosmin (HY-N0178). hidrosmin exerts a beneficial effect against diabetic nephropathy (DN) by reducing inflammation, oxidative stress, and senescence pathways. Hidrosmin can be used for the research of venous insufficiency and diabetes mellitus.
    Hidrosmin
  • HY-106103
    Seglitide 81377-02-8 99.30%
    Seglitide (MK-678) is an orally active, selective SSTR2 agonist and somatostatin analog. Seglitide also acts as a competitive Somatostatin receptor antagonist, with pA2 values of 6.50, 6.24 and 6.09 against SS14, SS25 and SS28, respectively. Seglitide produces only weak, transient inhibition of myocardial contractility in isolated right atria of guinea pigs. Seglitide inhibits glucagon secretion and reduces circulating insulin levels. Seglitide causes a sustained, reversible reduction in elevated systolic blood pressure in streptozotocin (HY-13753)-induced diabetic rats, but exerts no effect on spontaneously hypertensive rats. Seglitide induces membrane hyperpolarization and inhibits electrical excitability. Seglitide induces concentration-dependent contraction and significant desensitization in isolated distal colon of rats. Seglitide can be used in research related to hypertension complicated with insulin-dependent diabetes mellitus.
    Seglitide
  • HY-106158
    T-1095 209746-59-8 99.40%
    T-1095 is a selective and orally active Na+-glucose cotransporter (SGLT) inhibitor with IC50s of 22.8 µM and 2.3 µM for human SGLT1 and SGLT2, respectively. T-1095 can be used for diabetes research.
    T-1095
  • HY-107019
    Surinabant 288104-79-0 98.00%
    Surinabant (SR 147778) is an orally active, selective cannabinoid receptor type 1 CB1R antagonist. Surinabant is used in studies of obesity and alcoholism.
    Surinabant
  • HY-107384
    Asimadoline 153205-46-0 99.36%
    Asimadoline (EMD-61753) is an orally active, selective and peripherally active κ-opioid agonist with IC50s of 5.6 nM (guinea pig) and 1.2 nM (human recombinant). Asimadoline has low permeability across the blood brain barrier and has peripheral anti-inflammatory actions. Asimadoline ameliorates allodynia in diabetic rats and has the potential for irritable bowel syndrome (IBS).
    Asimadoline
  • HY-107623
    TC-MCH 7c 864756-35-4 99.79%
    TC-MCH 7c, a phenylpyridone derivative, is an orally available, selective and brain-penetrable MCH1R antagonist with an IC50 of 5.6 nM for hMCH1R. TC-MCH 7c has Kis of 3.4 nM and 3.0 nM of human and mouse MCH1R, respectively.
    TC-MCH 7c
  • HY-107728
    S 25585 263849-50-9 99.13%
    S 25585 is a potent and selective neuropeptide Y (NPY) Y5 receptor antagonist. S 25585 reduces food intake but not through blockade of the NPY Y5 receptor.
    S 25585
  • HY-107793
    Picosulfate sodium salt hydrate 1307301-38-7 98.0%
    Picosulfate sodium salt hydrate is the hydrate of Sodium Picosulfate (HY-B0544). Picosulfate sodium salt hydrate is an orally active contact irritant laxative. Picosulfate sodium salt hydrate inhibits the absorption of water and electrolytes, increasing their production. Picosulfate sodium salt hydrate can be used in colonoscopy applications.
    Picosulfate sodium salt hydrate
  • HY-107939
    Paramethasone Acetate 1597-82-6 98.0%
    Paramethasone Acetate is an orally active long-acting glucocorticoid. Paramethasone Acetate directly inhibits testicular aromatase, thereby reducing the synthesis of estradiol. Paramethasone Acetate suppresses the basal and midcycle luteinizing hormone surges in female animals and blocks estrogen synthesis. Paramethasone Acetate also decreases circulating levels of dihydrotestosterone, androstenedione and estradiol in male animals. Paramethasone Acetate inhibits cartilage degeneration and alleviates joint pathological damage in osteoarthritis models. Paramethasone Acetate can be used in research related to osteoarthritis and endocrinology.
    Paramethasone Acetate
  • HY-108047
    MK-0873 500355-52-2
    MK-0873 is a selective phosphodiesterase-4 (PDE4) inhibitor. MK-0873 increases intracellular levels of cyclic adenosine phosphate (cAMP) by inhibiting the activity of the PDE4 enzyme and subsequently activates protein kinase A (PKA). Activated PKA inhibits the activity of inflammatory cells and leads to direct relaxation of airway smooth muscle. MK-0873 can be used in studies of chronic obstructive pulmonary disease (COPD).
    MK-0873
  • HY-108049
    GW856464 851690-21-6 99.83%
    GW856464 is an antagonist for MCHR1. GW856464 can be studied in research for cardiovascular diseases and obesity.
    GW856464
  • HY-108059
    β-Cryptoxanthin 472-70-8 ≥99.0%
    β-Cryptoxanthin ((3R)-β-Cryptoxanthin) is an orally active carotenoid found in fruits and vegetables such as angerines, red peppers, and pumpkin. β-Cryptoxanthin inhibits prevents osteoclast formation and inhibits bone resorption. β-Cryptoxanthin maintains retinol status in vivo. β-cryptoxanthin shows anti-inflammation and anticancer activity. β-Cryptoxanthin can be used for the researches of osteoporosis and bladder carcer.
    β-Cryptoxanthin
  • HY-108271
    Mogroside III-A1 88901-42-2 99.27%
    Mogroside III-A1 is a triterpenoid glycoside and a nonsugar sweetener. Mogrosides are sweeter than sucrose. Mogrosides exhibit antioxidant, antidiabetic and anticancer activities.
    Mogroside III-A1
  • HY-108272
    Mogroside II-A2 88901-45-5 99.87%
    Mogroside II-A2 is a triterpenoid glycoside and a nonsugar sweetener. Mogrosides are sweeter than sucrose. Mogrosides exhibit antioxidant, antidiabetic and anticancer activities.
    Mogroside II-A2
  • HY-108600
    CGP-53353 145915-60-2 98.87%
    CGP-53353 (DAPH-7) is an potent PKC inhibitor with IC50s of 0.41 μM and 3.8 μM for PKCβII and PKCβI, respectively. CGP-53353 can inhibit glucose-induced cell proliferation and DNA synthesis in AoSMC and A10 cells. CGP-53353 can be used for researching atherosclerosis of diabetic patients.
    CGP-53353
  • HY-108621
    RS-25344 hydrochloride 152815-28-6 99.93%
    RS-25344 hydrochloride is a selective cAMP-phosphodiesterase 4 (PDE 4; PDE IV) inhibitor with an IC50 of 0.28 nM in human lymphocytes. RS-25344 hydrochloride has only weak inhibitory effects on PDE I, II, III (IC50 of >100 μM, 160 μM, 330 μM, respectively). RS-25344 hydrochloride has anti-inflammatory, memory- and cognition enhancing, and antineoplastic effects.
    RS-25344 hydrochloride
  • HY-109569
    Vitamin K2 11032-49-8 ≥98.0%
    Vitamin K2 is an orally active proliferation inhibitor. Vitamin K2 induces Autophagy and Apoptosis. Vitamin K2 reduces the levels of proinflammatory cytokines (such as IL-1β, TNF-α, and IL-6). Vitamin K2 inhibits cell growth in leukemia cells. Vitamin K2 can be used for the research of involutional osteoporosis, non-alcoholic fatty liver disease, ulcerative colitis, acute myeloid leukemia, myelodysplastic syndromes, and hepatocellular carcinoma.
    Vitamin K2
  • HY-110040
    L759633 174627-50-0 ≥99.0%
    L759633 is a potent and selective agonist of cannabinoid receptor (CB2) receptor, with Kis of 6.4 nM and 1043 nM for CB2 and CB1 receptors, respectively. L759633 can inhibit Forskolin-stimulated cAMP production.
    L759633
Cat. No. Product Name / Synonyms Application Reactivity